Researchers at the University of Miami are conducting a new survey for people living with spinal cord injuries (SCI) over the age of 18 to provide direct input on factors that encourage or discourage participation […]
Tcelna, a potential T-cell therapy for secondary-progressive MS as well as relapsing-remitting MS, is gearing up for its Phase IIb clinical trials. According to Opexa Therapeutics, Tcelna is the first-ever personalized T-cell therapy for MS, […]
On Sept. 3, 2012 Innate Immunotherapeutics announced that it has begun raising $10 million in order to test MIS416, a potential therapy for primary and secondary progressive MS, in Phase IIb clinical trials.
If you’ve ever wished your doctor would prescribe you a bunch of video games instead of an exercise program, the Veterans Administration’s Spinal Cord Injury Center in Palo Alto, Calif., may be coming to your […]